Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.51 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.49 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.49 |
| ▸ | GBA1 | P04062 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241250 | 0.98 | GBA1 (0.66) | GBA1SLC6A4MAOAMAOB | |
| Hydrochloric Acid SCHEMBL7669421 | 0.89 | GBA1 (0.59) | GBA1SLC6A4 | |
| SCHEMBL3044569 | 0.87 | GBA1 (0.56) | GBA1MAOB | |
| SCHEMBL82734 | 0.87 | GBA1 (0.61) | GBA1SLC6A4 | |
| SCHEMBL5781113 | 0.86 | GBA1 (0.56) | GBA1SLC6A4 | |
| Hydrochloric Acid SCHEMBL1532929 | 0.85 | GBA1 (0.51) | GBA1SLC6A4 | |
| SCHEMBL3358034 | 0.85 | GBA1 (0.59) | GBA1SLC6A4 | |
| SCHEMBL11537058 | 0.84 | GBA1 (0.58) | GBA1SLC6A4 | |
| SCHEMBL1609623 | 0.83 | MAOA (0.58) | MAOAMAOB | |
| SCHEMBL12736142 | 0.83 | GBA1 (0.53) | GBA1SLC6A4MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024043334-A1 | NOVEL PIPERAZINE DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION | 富士フイルム株式会社 | 2024-02-29 | — | — | WO | disclosed |
| EP-2607362-B1 | Piperidine and piperazine carboxylates as FAAH inhibitors | ASTELLAS PHARMA INC (JP) | 2014-12-31 | — | — | EP | disclosed |
| EP-1849773-B1 | Piperazine derivatives for the treatment of urinary incontinence and pain | ASTELLAS PHARMA INC (JP) | 2013-10-16 | — | — | EP | disclosed |
| EP-2607362-A1 | Piperidine and piperazine carboxylates as FAAH inhibitors | Astellas Pharma Inc. (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-7919495-B2 | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound | ASTELLAS PHARMA, INC. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7919494-B2 | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound | ASTELLAS PHARMA, INC. (JP) | 2011-04-05 | — | — | US | disclosed |
| US-7915261-B2 | Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound | ASTELLAS PHARMA, INC. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20100009972-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20100009971-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20080306046-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative | FMC CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1849773-A1 | PYRIDYL NON-AROMATIC NITROGENATED HETEROCYCLIC-1-CARBOXYLATE ESTER DERIVATIVE | Astellas Pharma Inc. (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-6486153-B1 | Phenylindole derivatives as 5-HT2A receptor ligands | MERCK SHARP & DOHME LTD. | 2002-11-26 | — | — | US | disclosed |
| EP-1180513-A1 | CYCLIC AMIDE COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-02-20 | — | — | EP | disclosed |
| EP-0701555-B1 | INDAZOLE DERIVATIVES | MERCK SHARP & DOHME (GB) | 1999-08-04 | — | — | EP | disclosed |
| WO-1999011619-A1 | PHENYLINDOLE DERIVATIVES AS 5-HT2A RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1999-03-11 | — | — | WO | disclosed |
| US-5665732-A | Indazole derivatives | MERCK, SHARP & DOHME LTD. (GB) | 1997-09-09 | — | — | US | disclosed |
| EP-0701555-A1 | INDAZOLE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1996-03-20 | — | — | EP | disclosed |
| WO-1994021626-A1 | INDAZOLE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1994-09-29 | — | — | WO | disclosed |
| US-5212181-A | 1-(3,4-dihydro-2-oxo-1H-quinolin-6-yl)-2-[4-(2-phenylethyl)piperidin-1-yl]et[4-(2-phenylethyl)piperidin-1-yl]ethanone, to their preparation and to their therapeutic application | SYNTHELABO (FR) | 1993-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306046-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative | FAAH, FAAH2, APEH | SLC6A4 713/4885MAOA 192/4885MAOB 156/4885 |
| US-20100009972-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | FAAH, FAAH2, CNR2 | SLC6A4 530/4885MAOA 60/4885MAOB 40/4885 |
| US-20100009971-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | FAAH, FAAH2, CNR1 | SLC6A4 548/4885MAOA 61/4885MAOB 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.